Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Interim Management Statement

10 May 2010 07:00

RNS Number : 5791L
Tarsus Group PLC
10 May 2010
 



 

 

 

TARSUS GROUP plc

 

Interim Management Statement

 

Tarsus Group Plc ("Tarsus" or "the Group"), the international business-to-business media group, is today publishing its Interim Management Statement relating to the period from the publication of its Preliminary Results on 8 March 2010 to 9 May 2010.

 

Trading Performance

 

Trading for the period has been in line with the Board's expectations. A summary of major developments includes:

 

§ US - continued recovery & momentum

 

The Medical division continues to gain momentum. The April Orlando event produced revenues well ahead of last year, driven by very strong growth from its education programmes. Exhibition and conference revenues also grew for the first time in 18 months.

 

§ France - management action retains margins within expectations

 

A number of small exhibitions have taken place in France since 8 March. As expected, the declining revenue trends experienced in the second half of 2009 have continued into the first half of 2010. Strong cost management has resulted in margins remaining within our expectations.

 

§ Emerging Markets

 

No material events have taken place since 8 March.

 

Financial Position

 

There have been no significant changes to the financial position of the Group since the publication of the Preliminary Results on 8 March 2010.

 

Outlook

 

At our preliminary results at the start of March we announced the launch of "Project 50/13" to accelerate our scale in Emerging Markets. Our business infrastructure in the region is now established and Tarsus has a much improved platform within Asia and the Middle East from which to continue to drive strong growth.

 

As in previous years, the Group's revenues remain heavily second-half weighted and, overall, forward bookings remain at a similar level to 2009.

 

The French portfolio is weighted towards the 4th quarter of the year and we are now seeing signs of stabilisation in that market, with forward bookings for 4th quarter events at similar levels to last year. Given the current economic outlook for Europe, we continue to remain cautious.

 

US sales are strong and ahead of 2009, driven mainly by our Off-Price (discount clothing) and Medical divisions. Labelexpo America's sales are marginally behind the previous edition, owing to smaller exhibitors booking later in the cycle.

 

In the Emerging Markets division, the Group's largest event this year is MEBA (business aviation) which takes place in Dubai for which forward bookings are well ahead of the previous cycle.

 

Our view of trading for 2010 is unchanged with long term exhibition trends intact. The recovery in the US economy is benefiting our business in that market and we are seeing good growth prospects and opportunities in Emerging Markets. Our strong brands, diversified portfolio of market leading events and increased focus on Emerging Markets leave Tarsus well positioned for the future.

 

Tarsus Group plc:

 

Douglas Emslie, Group Managing Director 020 8846 2700

Ashley Milton, Group Finance Director 020 8846 2700

 

Media:

 

Madano Partnership

Matthew Moth 020 7593 4000

 

Investors/Analysts:

 

IRfocus

Neville Harris 020 7593 4015

 

Scott Harris

Stephen Scott, Jeremy Wiseman 020 7653 0030

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSKKODKABKDOPK
Date   Source Headline
16th May 20197:00 amRNSTrading Update
9th May 20196:19 pmRNSBlock Listing Six Monthly Return
30th Apr 201910:14 amRNSTotal Voting Rights
16th Apr 20192:40 pmRNSDirector/PDMR Shareholding
2nd Apr 20193:43 pmRNSBlock listing Interim Review
1st Apr 201910:44 amRNSTotal Voting Rights
19th Mar 201911:42 amRNS2018 Annual Report
8th Mar 20194:36 pmRNSPrice Monitoring Extension
27th Feb 20197:00 amRNSFinal Results
6th Feb 20194:35 pmRNSPrice Monitoring Extension
31st Jan 201911:53 amRNSTotal Voting Rights
30th Jan 20197:00 amRNSOption agreement re Tarsus Connect
16th Jan 20194:22 pmRNSApplication for Admission
14th Jan 20197:00 amRNSYear-end Trading Update
13th Dec 20184:48 pmRNSScrip Dividend Circular (the "Circular")
30th Nov 20183:10 pmRNSTotal Voting Rights
20th Nov 20181:44 pmRNSApplication for Admission
6th Nov 20187:00 amRNSCapital Markets Seminar and Trading Update
1st Nov 20182:56 pmRNSTotal Voting Rights
18th Sep 20186:20 pmRNSDirector/PDMR Shareholding
14th Sep 201812:06 pmRNSResults of Placing
14th Sep 20187:00 amRNSAcquisitions and Placing of New Ordinary Shares
10th Sep 20183:18 pmRNSBlock Listing Six Monthly Return
31st Aug 20183:39 pmRNSTotal Voting Rights
24th Aug 201811:17 amRNSHalf-year Report
1st Aug 201811:54 amRNSTotal Voting Rights
26th Jul 20187:00 amRNSHalf-year Report
13th Jul 20182:34 pmRNSApplication for Admission - scrip dividend shares
13th Jul 20182:18 pmRNSDirector Declaration
21st Jun 20181:52 pmRNSResult of AGM
18th Jun 20183:37 pmRNSHolding(s) in Company
12th Jun 20184:41 pmRNSDirector/PDMR Shareholding
8th Jun 20183:45 pmRNSScrip Dividend Circular
1st Jun 201812:31 pmRNSTotal Voting Rights
21st May 20186:10 pmRNSNotice of AGM
17th May 20187:00 amRNSTrading Update
9th May 20187:00 amRNSBoard Changes
9th May 20187:00 amRNSBlock Listing Six Monthly Return
1st May 201811:45 amRNSTotal Voting Rights and Capital
20th Apr 201812:15 pmRNSDirector/PDMR Shareholding
20th Apr 201812:14 pmRNSDirector/PDMR Shareholding
18th Apr 20184:29 pmRNSNotification of Transactions
29th Mar 201810:50 amRNSTotal Voting Rights
22nd Mar 20185:01 pmRNS2017 Annual Report
9th Mar 20183:54 pmRNSDirector/PDMR Shareholding
6th Mar 201810:18 amRNSBlock Listing Six Monthly Return
5th Mar 20185:06 pmRNSDirector/PDMR Shareholding
28th Feb 20187:00 amRNSFinal Results
31st Jan 20189:40 amRNSTotal Voting Rights
12th Jan 201810:30 amRNSApplication for Admission - scrip dividend shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.